Astellas says stem cell research promising on kidney failure

Astellas Pharma and Japan university researchers say they have succeeded with preclinical work showing that induced pluripotent stem cells are capable of improving the symptoms of kidney failure.

The research, which was aimed at kidney failure resulting from diabetes or high blood pressure, used human cells transplanted into mice with kidney failure. The kidneys of the mice did not deteriorate, while a placebo given to mice led to acute failure, the research team reported.

The Astellas researchers worked with researchers at Kyoto University on the study.

- here's the story from Nikkei


Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.